A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese
Status:
Recruiting
Trial end date:
2025-04-04
Target enrollment:
Participant gender:
Summary
AZD9550 is in early development for the treatment of NASH, a type of liver disease that
commonly affects overweight and obese patients who have T2DM.
The purpose of this study is to investigate the safety, tolerability, and effects of
increasing doses of AZD9550 in overweight and obese participants aged 18 through 65 years
living with T2DM, and to investigate how AZD9550 is absorbed, distributed, and eliminated
from the body.